ORPHA:88917
X-linked Alport syndrome
Publications
785
90.1th percentile
Trials
3
Interventional, condition-specific
Researchers
1,201
Distinct authors in sample
Gene link
COL4A5
Definitive
Readiness
3/6
Stages with a signal
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0010520
- OMIM:301050
- UMLS:C4746986
Additional Mondo synonyms (3)
Alport syndrome 1, X-linked, X-linked dominant · Alport syndrome, X-linked · nephropathy and deafness, X-linked
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — COL4A5
- LiteraturePresent
785 matched papers (495 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
3 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (COL4A5).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
785
785 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
785 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
495 in the last 10 years · high confidence · 90.1th percentile (publications denominator)
Phrase hits: 785 · MeSH hits: 0
Who's working on it?
1,201
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Nozu K14 papers · 2026
Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Papers in Europe PMC - 02Savige J14 papers · 2026
Department of Medicine (Melbourne Health), The University of Melbourne, Parkville, Australia.
Papers in Europe PMC - 03Yamamura T10 papers · 2026
Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Papers in Europe PMC - 04Horinouchi T9 papers · 2026
Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Papers in Europe PMC - 05Gross O8 papers · 2026
Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany.
Papers in Europe PMC - 06Zhang Y8 papers · 2025
Department of Pediatrics, Peking University First Hospital, Beijing, China.
Papers in Europe PMC - 07Zhang J7 papers · 2025
Department of Nephrology and Rheumatology, Shanghai Children's Hospital, Shanghai Jiaotong University, Shanghai 200062, China.
Papers in Europe PMC - 08Li Y6 papers · 2026
Department of Sports Medicine, The Affiliated Calmette Hospital of Kunming Medical University, Kunming, Yunnan, China.
Papers in Europe PMC - 09Sakakibara N6 papers · 2026
Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Papers in Europe PMC - 10Sun L6 papers · 2026
Department of Nephrology and Rheumatology, Shanghai Children's Hospital, Children's Hospital of Shanghai Jiao Tong University, Shanghai, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
3
interventional trials for this specific condition
3 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 17 trials are registered for Alport syndrome, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
3 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 85.1th percentile).
high confidence · 85.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
3 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07523581·RECRUITING·EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
Conditions: Alport Syndrome, X-Linked · Alport Syndrome, Autosomal Recessive·Matched via name phrase
- NCT05133050·NOT YET RECRUITING·Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants
Conditions: Alport Syndrome·Matched via recall expansion
Broader category: Alport syndrome
17
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06731192·NOT YET RECRUITING·Human Umbilical Cord Mesenchymal Stem Cells for Alport Syndrome
Conditions: Alport Syndrome·Matched via name phrase
- NCT05003986·RECRUITING·Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Conditions: Focal Segmental Glomerulosclerosis · Minimal Change Disease · Immunoglobulin A Nephropathy · IgA Vasculitis·Matched via name phrase
- NCT04571658·RECRUITING·NEPTUNE Match Study
Conditions: Nephrotic Syndrome in Children · Focal Segmental Glomerulosclerosis · Minimal Change Disease · Minimal Change Nephrotic Syndrome·Matched via name phrase
- NCT07211685·RECRUITING·A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
Conditions: Alport Syndrome·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"X-linked Alport syndrome" OR "Alport syndrome 1, X-linked, X-linked dominant" OR "Alport syndrome, X-linked" OR "nephropathy and deafness, X-linked"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"X-linked Alport syndrome" OR "Alport syndrome 1, X-linked, X-linked dominant" OR "Alport syndrome, X-linked" OR "nephropathy and deafness, X-linked" OR "COL4A5"
Recall-expansion terms: COL4A5
Interventional trials matched via: phrase, recall-expansion (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 3 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"Alport syndrome"
Query health: ok — strategies attempted: phrase, recall-expansion; with hits: phrase, recall-expansion
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T03:25:24.337Z
